Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Photo: Josh Edelson/AFP via Getty Images
The Food and Drug Administration has approved an advanced treatment for mantle cell lymphoma, a rare type of cancer affecting white blood cells. The one-time therapy, made by Gilead Sciences, is branded as Tecartus.
Why it matters: This is the third federal approval of a CAR-T therapy, a new-age cancer treatment in which a person's own immune system cells are extracted, reengineered, and then infused back into the person's bloodstream.
The big picture: The other CAR-T therapies on the market are Kymriah (made by Novartis) and Yescarta (also made by Gilead).
By the numbers: Gilead set the list price of Tecartus at $373,000, the same as Yescarta.
- However, that does not include other extraneous hospitalization costs.
- Both of these drugs were part of Kite Pharma, which Gilead bought in 2017 for almost $12 billion.
Between the lines: Gilead said 87% of people who received Tecartus in a clinical trial responded to the infusion, but almost one out of five patients also experienced severe side effects associated with this kind of immunotherapy.
- The trial was not randomized because the cancer is rare, and consequently, the FDA required a warning for side effects and will closely watch the therapy for safety issues while it's on the market.